• Latest Posts

Dupixent gets EU nod for children with severe atopic dermatitis

Aditxt forms Adimune to focus on immune modulation therapies

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

A new treatment for tackling epidermolysis bullosa

Prurigo nodularis treatment recommended for EU approval  

Treatment for adults with chronic skin condition approved by FDA


Kamari Pharma raises $8M in investment for development of drugs for skin diseases

Regeneron and Sanofi announce published trial results in children with dermatitis

Ilya Pharma partners with US Defense Department for wound healing drug

Treatment for adults with moderate to severe psoriasis approved by FDA

Lutris Pharma radiation trial brings positive results for breast cancer patients

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug